280 related articles for article (PubMed ID: 19231905)
1. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.
Mueller D; Weyler E; Gandjour A
Pharmacoeconomics; 2008; 26(6):513-36. PubMed ID: 18489201
[TBL] [Abstract][Full Text] [Related]
4. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Schwenkglenks M; Lippuner K
Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
Nayak S; Roberts MS; Greenspan SL
Ann Intern Med; 2011 Dec; 155(11):751-61. PubMed ID: 22147714
[TBL] [Abstract][Full Text] [Related]
6. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
7. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.
Si L; Winzenberg TM; Chen M; Jiang Q; Neil A; Palmer AJ
Osteoporos Int; 2016 Jul; 27(7):2259-2269. PubMed ID: 26815042
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
[TBL] [Abstract][Full Text] [Related]
9. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis.
Marín F; López-Bastida J; Díez-Pérez A; Sacristán JA;
Calcif Tissue Int; 2004 Mar; 74(3):277-83. PubMed ID: 14708042
[TBL] [Abstract][Full Text] [Related]
12. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
14. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Sowa PM; Downes MJ; Gordon LG
J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
[TBL] [Abstract][Full Text] [Related]
16. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
18. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
Osteoporos Int; 2005 Dec; 16(12):1883-93. PubMed ID: 16133649
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women.
Panichkul S; Panichkul P; Sritara C; Tamdee D
Gynecol Obstet Invest; 2006; 62(2):89-96. PubMed ID: 16636570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
